Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794703 | 0.86 | PARP1 (0.46) | DAOPARP1HTR1ADRD2HTR2A | |
| SCHEMBL6300121 | 0.84 | PARP1 (0.46) | DAOPARP1CYP1A2MEN1KMT2A | |
| SCHEMBL30704833 | 0.80 | SMN1; SMN2 (0.53) | DAOPARP1CYP1A2CYP2C19 | |
| SCHEMBL6027770 | 0.80 | SMN1; SMN2 (0.53) | DAOPARP1CYP1A2CYP2C19 | |
| SCHEMBL6294349 | 0.78 | PARP1 (0.52) | DAOPARP1CYP1A2P2RX4HTR1A | |
| SCHEMBL17242599 | 0.78 | PARP1 (0.49) | DAOPARP1BACE1IDO1 | |
| SCHEMBL7022854 | 0.77 | CYP1A2 (0.59) | CYP1A2MEN1KMT2A | |
| SCHEMBL6295463 | 0.76 | PARP1 (0.50) | DAOPARP1HTR1ADRD2HTR2A | |
| SCHEMBL6295245 | 0.75 | PARP1 (0.53) | DAOPARP1CYP1A2HTR1ADRD2 | |
| SCHEMBL6027805 | 0.74 | CYP1A2 (0.64) | DAOPARP1CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259192-A1 | Method for cleaving the human growth hormone gh | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-12-23 | — | — | US | claimed |
| US-20040044013-A1 | 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-03-04 | — | — | US | claimed |
| US-20040259192-A1 | Method for cleaving the human growth hormone gh | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20040044013-A1 | 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044013-A1 | 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors | MMP2, MMP3, MMP1 | DAO 114/4885PARP1 308/4885CYP1A2 466/4885 |
| US-20040259192-A1 | Method for cleaving the human growth hormone gh | MMP3, MMP25, MMP17 | DAO 2873/4885PARP1 1057/4885CYP1A2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.